These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 20227796

  • 1. [Treatment of advanced hepatocellular carcinoma].
    Forner A, Rodríguez De Lope C, Reig M, Bruix J.
    Gastroenterol Hepatol; 2010; 33(6):461-8. PubMed ID: 20227796
    [Abstract] [Full Text] [Related]

  • 2. Evolution of systemic therapy of advanced hepatocellular carcinoma.
    Yau T, Chan P, Epstein R, Poon RT.
    World J Gastroenterol; 2008 Nov 14; 14(42):6437-41. PubMed ID: 19030192
    [Abstract] [Full Text] [Related]

  • 3. Sorafenib in hepatocellular carcinoma.
    Josephs DH, Ross PJ.
    Br J Hosp Med (Lond); 2010 Aug 14; 71(8):451-6. PubMed ID: 20852487
    [Abstract] [Full Text] [Related]

  • 4. Advanced hepatocellular carcinoma. Review of targeted molecular drugs.
    Alves RC, Alves D, Guz B, Matos C, Viana M, Harriz M, Terrabuio D, Kondo M, Gampel O, Polletti P.
    Ann Hepatol; 2011 Aug 14; 10(1):21-7. PubMed ID: 21301005
    [Abstract] [Full Text] [Related]

  • 5. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T, Pang R, Chan P, Poon RT.
    Expert Opin Pharmacother; 2010 Sep 14; 11(13):2187-98. PubMed ID: 20707757
    [Abstract] [Full Text] [Related]

  • 6. [The hepatocellular carcinoma: alternative therapeutical strategies].
    Spangenberg HC, Thimme R, Mohr L, Blum HE.
    Zentralbl Chir; 2007 Aug 14; 132(4):322-7. PubMed ID: 17724635
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Sorafenib in advanced hepatocellular carcinoma.
    Palmer DH.
    N Engl J Med; 2008 Dec 04; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB.
    JAMA; 2010 Nov 17; 304(19):2154-60. PubMed ID: 21081728
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G, SARAH Trial Group.
    Trials; 2014 Dec 03; 15():474. PubMed ID: 25472660
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Developing better treatments in hepatocellular carcinoma.
    Duffy A, Greten T.
    Expert Rev Gastroenterol Hepatol; 2010 Oct 03; 4(5):551-60. PubMed ID: 20932140
    [Abstract] [Full Text] [Related]

  • 18. Management of hepatocellular carcinoma: beyond sorafenib.
    Chan SL, Mok T, Ma BB.
    Curr Oncol Rep; 2012 Jun 03; 14(3):257-66. PubMed ID: 22434314
    [Abstract] [Full Text] [Related]

  • 19. [Current therapy for hepatocellular carcinoma].
    Ikeda K.
    Nihon Rinsho; 2010 Jun 03; 68(6):1129-36. PubMed ID: 20535967
    [Abstract] [Full Text] [Related]

  • 20. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.
    Horger M, Lauer UM, Schraml C, Berg CP, Koppenhöfer U, Claussen CD, Gregor M, Bitzer M.
    BMC Cancer; 2009 Jun 28; 9():208. PubMed ID: 19558720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.